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It will be noticed that clinical lobar pneumonia in infants of the 0-6 months age group is comparatively rare, but that when it does occur it tends to carry with it a death rate as high as that of atypical pneumonia; thereafter atypical pneumonia is about twice as fatal as lobar.
The importance of pneumonia as a social danger to the children of the Irish Free State is shown by reference to the official statistics published by the Eire Government. These show that in 1936 and 1937 of every 1,000 children born at full term in Eire, 8-96 and 8-34 respectively died of certified pneumonia under one year of age. The disease ranks third as the greatest slayer of full-time infants in Dublin in the first year of life.
Clinical evidence has now firmly established the value of chemotherapeutic treatment in the adult pneumonias, but little evidence has yet been collected of the value or otherwise of chemotherapy in treating the pneumonias of infants and young children. Tables 5 and 6 were drawn up after careful study of the records of three Dublin hospitals. The number of cases makes statistical deductions inconclusive, but there would appear to have been a tendency for the death rate from atypical pneumonia in the first year of life to be lowered, whilst the rates in lobar pneumonia for the first two years of life appear to have been unaffected. As these figures appeared unsatisfactory compared with the reported results from the newer methods of therapy in the adult pneumonias, an investigation of the results of individual methods of treatment in these three hospitals was undertaken (table 7) . From this table, it will be seen that the best results may be expected from the combined use of sulphapyridine with anti-pneumococcal serum, and that in the very young, chemotherapeutic measures alone may not offer the best chances of recovery. This point depends largely on two factors, viz. differences in immunity factors in children, and differences in the anatomico-pathological type of disease in young children.
Immunity factors in children
The principal antibody mechanisms involved in pneumococcal infections are agglutination and precipitation. Complete dissolution of the organisms is impossible without additional phagocytic activity, but there is no evidence to show that such activity is lacking in infants.
Fleming (Fleming, 1938; Maclean, Rogers and Fleming, 1939) has shown that the addition of a specific antibacterial serum to a mixture of blood and M and B 693 increases its antibacterial action to pneumococci, and has further substantiated these findings by experiments in mice and rabbits (1939) . The function of the specific antiserum is the neutralization of the specific soluble substance, which is the toxic substance proper of the pneumococcal capsule. This neutralization occurs in the circulation and peripheral organs (Kempf and Nungester, 1939) , and apparently follows a mathematical ratio. The following experiment was carried out in order to determine whether the very young produce such antibacterial substances or not.
Technique. A slide agglutination technique, described by Bullowa (1937) , was used. A drop of the patient's serum was mixed with a drop of the specific antigen consisting of killed suspensions of pneumococci, two billions per c.c. on glass slides. Antigens of types 1, 2, 3, 4, 5, 6, 7, 8 and 14 pneumococci were used. Slides were air cooled and fixed in a solution of 94 c.c. water, 1 c.c. glacial acetic acid, 5 c.c. formalin (40 per cent. formaldehyde). When dried they were stained for a few seconds with Loffler's alkaline methylene blue stain, dried and examined by 1/12 oil immersion lens. Control slides were also put up consisting of (i) saline or normal blood with antigen; (ii) antigen with type specific serum of known agglutination titre. The agglutination is symbolically expressed as one of four degrees: -, , = ,-.
A special polyvalent pneumococcal vaccine containing all the thirty-two types of pneumococci with several strains of certain types, was given by subcutaneous injection to healthy subjects of various ages, and their sera were examined by the above technique on the third and seventh days following inoculation. Injections were given on three successive days as follows: 0-1 c.c. 0-2 c.c. and 0-4 c.c. The vaccine contained 100 million organisms per 0-1 c.c., and was prepared by Professor Alexander Fleming in the Inoculation Department of St. Mary's Hospital, London.
Results. Table 8 shows the results in six subjects aged eight weeks to fourteen years. Table 9 shows the results of six subjects aged six years to sixty-eight years using doses of 0-2, 0-5 and 1-0 c.c. respectively at the same time intervals. These experiments tend to show that the anti-pneumococcal antibodyproducing mechanism of very young children is incapable of producing the necessary immunological substances necessary to complete the destructive powers offered by chemotherapy alone. In adults, sensitizing doses of pneumococci inhaled from time to time have given to the antibody mechanism the potential energy necessary to bring it rapidly into action when pathogenproducing organisms gain entry into the tissues. Sulphapyridine in adults often kills the pneumococci so rapidly and effectively that the stimulus to antibody production is eliminated. This may explain the delayed resolution so often seen in such cases. It is important to maintain therapeutic levels of the drug in the blood stream for seven to ten days. There is evidence to show that in adults sulphathiazole (Kneeland and Mulliken, 1940) may prove a better drug because, being less rapidly bactericidal, there is more opportunity for the immunity mechanism to come into action. This should tend to prevent acute relapse and perhaps delayed resolution. This brings out the important point that the assessment of treatment in the pneumonias of children should be considered strictly from the age group point of view. Once a child passes the age of two years it enters, immunologically speaking, the realm of the adult pneumonias. The reason for this is not only a change in the mode of the immunity response, but also a change in the anatomico-pathological type of the disease. Special considerations. Since sulphapyridine is insoluble in relatively neutral solutions, its absorption from the gut is likely to be influenced by the changes in pH which fluids may undergo in the small intestine, and by the varying rapidity with which fluids may pass along the gut in health and disease. If diarrhoea or vomiting is present there will not only be a loss of sulphapyridine from the bowel or stomach but the actual amount of fluid in the bowel may be so reduced as to render the solution of an adequate therapeutic amount of the drug impossible. Again, if the bacterial flora of the bowel is such as to reduce the pH of its contents, solubility of sulphapyridine may also be reduced. Thus, apart from combating dehydration and acidosis, the parenteral administration of glucose-saline with sodium sulphapyridine has an important r6le in therapy. In such an acute disease as pneumonia it may be advisable in severe cases to control the level of blood sulphapyridine by chemical estimation. The method described by Werner (1939) These findings closely agree with the dosage worked out by Hynes (1940) at the Hospital for Sick Children, Great Ormond Street.
In poorly nourished and maldeveloped children, a severe acute secondary anaemia is liable to occur, especially in the presence of septicaemia or when chemotherapy is given over a prolonged period. Such anaemia reduces considerably the immunity response. Early blood transfusion is often a life-saving procedure in such cases. The general response of the child to treatment should be the main guiding factor for its use, since haemoglobin estimations are often misleading owing to the variation of blood-concentration which occurs in severely sick children.
The use of type specific serum is important. Curnen (1939) , at a meeting of the Massachusetts Medical Society, gave a report on thirty-four cases of type XIV pneumonia in children of whom twenty-two were under two years of age, treated with type specific serum alone. All survived, and all but three with complications or a mixed infection responded promptly to adequate doses of the serum. Bullowa had an 8-5 per cent. mortality in 330 cases between 1934 and 1937 . Don et al., 1940 shown that the best results in adults with pneumococcal septicaemia are obtained by the use of specific serum combined with chemotherapy. There is a 100 per cent. mortality amongst untreated cases of pneumococcal septicaemia in children under two years of age. The necessity of combined therapy is therefore most urgent in young children with pneumococcal septicaemia.
Special mention should be made of pneumonia occurring in malnourished, underdeveloped or premature infants. Modern methods of treatment have given these a better chance of recovery, but the necessity of maintaining nutrition whilst the struggle is in progress is still of vital importance. Breast feeding should be continued if practicable, but if this is impossible, fresh or stored breast-milk from a healthy donor, preferably the mother, should be obtained. 
